Biotechnology advances, 2013-03, Vol.31 (2), p.140-153
2013
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics
- Ist Teil von
- Biotechnology advances, 2013-03, Vol.31 (2), p.140-153
- Ort / Verlag
- Kidlington: Elsevier Inc
- Erscheinungsjahr
- 2013
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Both conventional and innovative biomedical approaches require cost-effective protein drugs with high therapeutic potency, improved bioavailability, biocompatibility, stability and pharmacokinetics. The growing longevity of the human population, the increasing incidence and prevalence of age-related diseases and the better comprehension of genetic-linked disorders prompt to develop natural and engineered drugs addressed to fulfill emerging therapeutic demands. Conventional microbial systems have been for long time exploited to produce biotherapeutics, competing with animal cells due to easier operation and lower process costs. However, both biological platforms exhibit important drawbacks (mainly associated to intracellular retention of the product, lack of post-translational modifications and conformational stresses), that cannot be overcome through further strain optimization merely due to physiological constraints. The metabolic diversity among microorganisms offers a spectrum of unconventional hosts, that, being able to bypass some of these weaknesses, are under progressive incorporation into production pipelines. In this review we describe the main biological traits and potentials of emerging bacterial, yeast, fungal and microalgae systems, by comparing selected leading species with well established conventional organisms with a long run in protein drug production.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0734-9750eISSN: 1873-1899DOI: 10.1016/j.biotechadv.2012.09.001Titel-ID: cdi_proquest_miscellaneous_1288994760
- Format
- –
- Schlagworte
- Aggregation, Animals, bioavailability, biocompatibility, Biological and medical sciences, Biotechnology, Biotherapeutics, Chlamydomonas reinhardtii - genetics, Chlamydomonas reinhardtii - metabolism, cost effectiveness, Cost-Benefit Analysis, drugs, Escherichia coli - genetics, Escherichia coli - metabolism, Fundamental and applied biological sciences. Psychology, hosts, human population, Industrial Microbiology - economics, Industrial Microbiology - methods, longevity, Mammals, microalgae, Microbial cells, pharmacokinetics, Pichia - genetics, Pichia - metabolism, pipelines, post-translational modification, Protein Engineering - economics, Protein Engineering - methods, Protein Folding, Protein Processing, Post-Translational, Protein production, Pseudoalteromonas - genetics, Pseudoalteromonas - metabolism, Recombinant protein, Recombinant Proteins - chemistry, Recombinant Proteins - isolation & purification, Recombinant Proteins - metabolism, Recombinant Proteins - therapeutic use, Saccharomyces cerevisiae - genetics, Saccharomyces cerevisiae - metabolism, therapeutics, Trichoderma - genetics, Trichoderma - metabolism, yeasts